| Supplementary Protection Certificate (SPC) Summary | |||
| SPC No. | 2016/025 | ||
|---|---|---|---|
| Date of filing | 02/06/2016 | ||
| Notification of Application Published | 29/06/2016 | ||
| Status | Granted | ||
| Notification of Grant Published | 31/03/2021 | ||
| Date of Expiry of SPC | 20/07/2030 | ||
| Applicant |
Amgen Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 UNITED STATES OF AMERICA |
||
| Patent Number | 2215124 | ||
| Title of Invention | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) | ||
| Date of Expiry of Patent | 21/08/2028 | ||
| Product Type | Medicinal Product | ||
| Product Identity | Evolocumab | ||
| Market Authorisation | Ireland | ||
| Authorisation No | EU/1/15/1016/001 to EU/1/15/1016/005 | ||
| Authorisation Date | 17/07/2015 | ||
| Identity of Product Authorised | Repatha - Evolocumab | ||
| Address for Service |
Anne Ryan & Co 2 Crofton Terrace Dun Laoghaire Co. Dublin A96 V6P7 IRELAND |
||
| Renewal Fees | |||
| 02/03/2021 | Supplementary Protection Certificate Number 2016/025, having an expiry date of 20/07/2030 granted on 02/03/2021. | ||
| 04/04/2023 | Application for an extension of the duration of Supplementary Protection Certificate No. 2016/025 filed on 03/04/2023. | ||